Skip to main content

Select Drug Profiles

Original Research

Evolving Trends in Insulin Delivery: In Pursuit of Improvements in Diabetes Management

Firas Akhrass, MD, Nancy Skinner, RN, Kimberly Boswell, MD, Luther B. Travis, MD

Stakeholder Perspective

Diabetes: An Epidemic of Disastrous Proportions

by James V. Felicetta, MD

Original Research

Healthcare Costs Associated with Switching from Brand to Generic Levothyroxine

Michael Katz, PharmD, Joseph Scherger, MD, MPH, Scott Conard, MD, Leslie Montejano, CCRP, Stella Chang, MPH

Stakeholder Perspective

Health Insurance Premium Increases for Large Employers

by Michael S. Jacobs, RPh

Practice Management

Pay-for-Performance Initiatives: Modest Benefits for Improving Healthcare Quality

Amit Sura, MD, MBA, Nirav R. Shah, MD,MPH

Stakeholder Perspective

The Many Challenges of Pay-for-Performance Programs

by Steven T. Kmucha, MD, JD

Practice Management

Pharmacogenomics and Drug Development

Michael F. Murphy, MD, PhD

Practice Management

First Anti-Inflammatory Generic Drug Promising New Therapy for Diabetes

Dalia Buffery, MA, ABD

The Cardiovascular Pipeline: ACC 2010 Features Late-Stage Drugs

Conference Highlights NCCN

NCCN Panel Debates the Economics of Cancer Care

Caroline Helwick

Conference Highlights NCCN

PET Scans Not Recommended for Most Patients with Breast Cancer: Potential New Controversy in Breast Cancer Testing

Caroline Helwick

Practice Management

Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point?

Rebecca Hyde, Diana Dobrovolny

Stakeholder Perspective

Orphan Drugs: The Potential Impact of Generic Biologics

by Kavita V. Nair, PhD

Practice Management

Physicians' Perceptions of Reimbursement as a Barrier to Comprehensive Diabetes Care

Alyssa Pozniak, PhD, Lois Olinger, MA, Victoria Shier, MA

Stakeholder Perspective

Diabetes Management Strategies: More Money Does Not Equal Better Care

by Gary M. Owens, MD

Page 240 of 244
Results 2391 - 2400 of 2434